Summarized by Masters of Longevity from Longevity Technology.
A concise preview of a news article about a clinical trial testing an amylin-based obesity diabetes drug, explaining what the reader will learn and why it matters.
Key Takeaways
- Petrelintide produced 7.4% to 9.2% average weight loss over 28 weeks.
- Stomach-related side effects were mostly mild, causing 1.9% treatment discontinuation.
- Phase 3 trials are underway to evaluate longer-term effects and cardiovascular outcomes.
